| Ryoncil (remestemcel-L) / Mallinckrodt, Mesoblast |
Mesoblast_COVID-19: Remestemcel-L Looks Promising in COVID-19 Patients With Moderate to Severe ARDS |
|
|
| Not yet recruiting | 3 | 0 | US | Ryoncil (remestemcel-L) - Mallinckrodt, Mesoblast, JCR Pharma | Mesoblast, JCR Pharma, Mallinckrodt | Moderate to Severe ARDS | | | | |
NCT04548583: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis |
|
|
| Recruiting | 1/2 | 24 | US | Remestemcel-L, Placebo | The Cleveland Clinic, Mesoblast, Inc. | Crohn Colitis | 10/23 | 10/23 | | |
NCT04543994: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) |
|
|
| Recruiting | 1/2 | 24 | US | Remestemcel-L, Placebo | The Cleveland Clinic, Mesoblast, Inc. | Ulcerative Colitis | 11/23 | 11/23 | | |
NCT00759018: Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD |
|
|
| No Longer Available | N/A | | Canada, US | remestemcel-L, Prochymal®, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells | Mesoblast, Inc. | Graft vs Host Disease, Graft-Versus-Host Disease | | | | |
|
NCT00826046: Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD) |
|
|
| No Longer Available | N/A | | US | Prochymal®, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells | Mesoblast, Inc. | Graft-Versus-Host Disease | | | | |
NCT01510431: Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease |
|
|
| No Longer Available | N/A | | US | PROCHYMAL (remestemcel-L) | Mesoblast, Inc. | Crohn's Disease | | | | |
NCT04366830: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection |
|
|
| No Longer Available | N/A | | US | Remestemcel-L | Mesoblast International SÃ rl | Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19 | | | | |
NCT04456439: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) |
|
|
| Available | N/A | | NA | Remestemcel-L, Hydrocortisone, Diphenhydramine, Benadryl® | Mesoblast International Sàrl | Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) | | | | |
